Indivior Pharmaceuticals — Key Risks
Heavy Dependence on a Single Product, SUBLOCADE, for Revenue
SUBLOCADE, a monthly injectable buprenorphine treatment, accounted for 69% of total net revenues in 2025, up from 58% in 2023. This concentration means any setback — a competing product, a coverage cut, a manufacturing problem, or a patent challenge — could hit the company's finances hard. A direct competitor, BRIXADI, already launched in the U.S. in 2023.
A Long and Costly History of Litigation With More on the Way
Indivior has paid out over $1.3 billion in legal settlements over the past few years, covering antitrust claims, DOJ fraud charges, and opioid crisis lawsuits. Active cases still include a large number of dental injury lawsuits (claiming SUBOXONE Film caused tooth damage) and U.K. stockholder claims. These proceedings drain cash, distract management, and carry real risk of additional large judgments.
Medicaid Cuts Could Directly Shrink the Patient Base
Indivior's products treat opioid use disorder (OUD), a condition disproportionately covered by Medicaid. Congressional proposals under the 2025 budget reconciliation act could reduce Medicaid eligibility or limit coverage of higher-cost OUD treatments. Since Medicaid is a primary payer for this patient population, funding cuts could meaningfully reduce the number of patients who can access SUBLOCADE.
Ongoing FTC and State Compliance Obligations Through 2030
As part of past settlements, Indivior operates under a Stipulated Order with the FTC and a similar agreement with 41 state attorneys general. These require detailed reporting on product launches, pricing, and corporate activity. Violating these terms could trigger criminal contempt charges. The company must navigate these constraints on normal business decisions until November 2030.
Sole-Source Supply Chain for Key Ingredients
For most products, including SUBLOCADE, Indivior relies on a single supplier for critical raw materials and active ingredients (including buprenorphine). Switching to a new supplier takes an average of 36 months and requires FDA approval. A disruption at any one of these suppliers — whether from a quality failure, geopolitical event, or natural disaster — could halt product supply with very few short-term alternatives.
Leveraged Balance Sheet With Negative Working Capital
Current liabilities exceed current assets by over $250 million, and total liabilities exceed total assets by approximately $100 million. The company carries a term loan with a remaining balance of $333 million and financial covenants that tighten in late 2026. If revenues fall, the company's ability to meet these covenants and fund operations comes under real pressure.
Restructuring Costs May Exceed Estimates
In late 2025, Indivior exited several international markets (including the U.K., Ireland, and others), discontinued OPVEE, and restructured its R&D organization — recognizing $127 million in exit costs. The company acknowledges that actual costs could differ materially from estimates due to local employment laws, facility costs, inventory write-downs, and contract termination terms.